全球多重檢測市場

預計到 2030 年，全球多重檢測市場規模將達到 60 億美元

全球多重檢測市場規模預計在2024年為41億美元，預計到2030年將達到60億美元，2024年至2030年的複合年成長率為6.4%。報告分析的細分市場之一——耗材——預計複合年成長率為6.9%，到分析期結束時規模將達到37億美元。分析期間內，設備細分市場的複合年成長率預計為5.4%。

美國市場規模估計為 11 億美元，中國市場預期複合年成長率為 9.6%

預計到2024年，美國多重檢測市場規模將達11億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到14億美元，在2024-2030年的分析期間內，複合年成長率為9.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.5%和6.1%。在歐洲，預計德國市場的複合年成長率為3.8%。

全球多重分析市場－主要趨勢與促進因素摘要

什麼是多重分析以及它們如何用於研究和診斷？

多重檢測是一種先進的診斷工具，可同時檢測和分析單一樣本中的多種生物標記（例如蛋白質、基因和其他分子）。此類檢測廣泛應用於科學研究、臨床診斷和藥物開發，以更準確、更有效率地分析複雜的生物過程或檢測疾病。與一次測量一種分析物的傳統檢測不同，多重檢測透過同時評估多個標靶提供全面的概覽，從而節省時間、降低成本並提高數據吞吐量。此類檢測在腫瘤學、免疫學和感染疾病等領域至關重要，了解多種生物標記有助於更準確的診斷和製定個人化治療策略。

哪些技術進步將形塑多重分析的未來？

生物技術和分子診斷技術的進步正在推動多重檢測變得更加靈敏、準確和可擴展。次世代定序儀(NGS) 技術和微陣列平台的開發顯著提高了同時分析大量基因和蛋白質數據的能力。此外，螢光和化學冷光檢測方法的進步提高了多重檢測的靈敏度和準確度，使得低濃度生物標記的檢測成為可能。與人工智慧 (AI) 和機器學習的結合實現了更先進的數據分析，幫助研究人員和臨床醫生更有效地解讀複雜的檢測結果。這些技術創新正在擴大多重檢測在伴隨診斷、生物標記發現和個人化醫療等領域的應用。

個人化醫療的轉變如何推動多重檢測的需求？

個人化醫療日益成為趨勢，即根據患者獨特的基因、分子和環境特徵為其量身定做治療方案，這推動了對多重檢測的需求。這些檢測使醫療保健提供者能夠同時分析多種生物標記物，從而更全面地了解患者的健康和疾病狀態。例如，在腫瘤學領域，多重檢測可用於識別可指南標靶治療的特定突變或基因表現。在單次檢測中檢測和監測多種疾病相關標記的能力還可以同時評估多種結果，從而提高藥物開發和臨床試驗的效率。這種對更個人化和精準醫療保健的追求，是多重檢測市場的主要成長動力。

推動多重檢測市場成長的關鍵因素有哪些？

多重檢測市場的成長受到多種因素的推動，包括分子診斷的進步、慢性病盛行率的上升以及對個人化醫療的不斷成長的需求。高通量平台和增強檢測方法的開發等技術創新正在提高多重檢測的準確性並使其應用範圍更廣。癌症和其他複雜疾病的發生率不斷上升也推動了這些檢測在研究和臨床環境中的應用，在這些環境中，了解多種生物標記對於診斷和治療至關重要。此外，伴隨診斷的擴展（使用多重檢測為患者匹配特定治療方法）進一步推動了需求。多重檢測在藥物開發的應用日益增多，尤其是在生物標記主導的新藥臨床試驗中，也是市場成長的主要因素。

部分

產品（耗材、儀器、軟體和服務）；類型（蛋白質檢測、核酸檢測、細胞檢測）；最終用戶（製藥和生物技術公司、醫院和研究機構、參考實驗室、其他最終用戶）

調查企業範例（共11家值得關注的企業）

• Abcam PLC
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Illumina, Inc.
• Luminex Corporation
• Merck KgaA
• Meso Scale Diagnostics, LLC.
• Olink
• Qiagen NV
• Quanterix Corporation
• Randox Laboratories Ltd.
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Multiplex Assays Market to Reach US$6.0 Billion by 2030

The global market for Multiplex Assays estimated at US$4.1 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.6% CAGR

The Multiplex Assays market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Multiplex Assays Market - Key Trends & Drivers Summarized

What Are Multiplex Assays and How Are They Used in Research and Diagnostics?

Multiplex assays are advanced diagnostic tools that allow the simultaneous detection and analysis of multiple biological markers (such as proteins, genes, or other molecules) in a single sample. These assays are widely used in research, clinical diagnostics, and drug development to analyze complex biological processes or detect diseases with higher accuracy and efficiency. Unlike traditional assays that measure one analyte at a time, multiplex assays provide a comprehensive overview by assessing multiple targets simultaneously, thus saving time, reducing costs, and increasing data throughput. These assays are essential in fields like oncology, immunology, and infectious diseases, where understanding multiple biomarkers can lead to more accurate diagnoses and personalized treatment strategies.

What Technological Advances Are Shaping the Future of Multiplex Assays?

Advancements in biotechnology and molecular diagnostics are transforming multiplex assays, making them more sensitive, accurate, and scalable. The development of next-generation sequencing (NGS) technologies and microarray platforms has significantly enhanced the ability to analyze large volumes of genetic and protein data simultaneously. Furthermore, advances in fluorescent and chemiluminescent detection methods have improved the sensitivity and precision of multiplex assays, allowing for the detection of lower concentrations of biomarkers. Integration with artificial intelligence (AI) and machine learning is enabling more sophisticated data analysis, helping researchers and clinicians interpret complex assay results more effectively. These technological innovations are expanding the use of multiplex assays in areas such as companion diagnostics, biomarker discovery, and personalized medicine.

How Is the Shift Toward Personalized Medicine Driving the Demand for Multiplex Assays?

The growing trend toward personalized medicine, which tailors treatments to individual patients based on their unique genetic, molecular, and environmental profiles, is significantly boosting the demand for multiplex assays. These assays enable healthcare providers to analyze multiple biomarkers at once, offering a more comprehensive understanding of a patient’s health and disease status. In oncology, for example, multiplex assays are being used to identify specific mutations or gene expressions that can guide targeted therapies. The ability to detect and monitor several disease-related markers in a single test is also enhancing the efficiency of drug development and clinical trials, where multiple outcomes can be evaluated simultaneously. This push toward more personalized and precise healthcare is a major growth driver for the multiplex assays market.

What Are the Key Growth Drivers in the Multiplex Assays Market?

The growth in the multiplex assays market is driven by several factors, including advancements in molecular diagnostics, the rising prevalence of chronic diseases, and the increasing demand for personalized medicine. Technological innovations, such as the development of high-throughput platforms and enhanced detection methods, are making multiplex assays more accurate and accessible for a wider range of applications. The growing incidence of cancer and other complex diseases is also pushing the adoption of these assays in research and clinical settings, where understanding multiple biomarkers is critical for diagnosis and treatment. Additionally, the expansion of companion diagnostics, where multiplex assays are used to match patients with specific therapies, is further driving demand. The increasing use of multiplex assays in pharmaceutical development, especially in the context of biomarker-driven drug trials, is another significant factor contributing to market growth.

SCOPE OF STUDY:

The report analyzes the Multiplex Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Consumables, Instruments, Software & Services); Type (Protein Assays, Nucleic Acid Assays, Cell-Based Assays); End-Use (Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

• Abcam PLC
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Illumina, Inc.
• Luminex Corporation
• Merck KgaA
• Meso Scale Diagnostics, LLC.
• Olink
• Qiagen NV
• Quanterix Corporation
• Randox Laboratories Ltd.
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Global Economic Update
  • Multiplex Assays - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Demand for High-Throughput Diagnostic Testing Drives Adoption of Multiplex Assays
  • Rising Prevalence of Chronic and Infectious Diseases Expands Addressable Market for Multiplex Assays in Diagnostics
  • Increasing Focus on Personalized Medicine and Biomarker Discovery Strengthens Business Case for Multiplex Assays
  • Growth in Pharmaceutical R&D and Drug Development Fuels Demand for Multiplex Assays in Drug Screening
  • Technological Advancements in Multiplex Assay Platforms Propel Innovation in Precision Diagnostics
  • Rising Use of Multiplex Assays in Oncology Expands Opportunities for Cancer Diagnosis and Treatment
  • Increasing Adoption of Multiplex Assays in Immunology Research Strengthens Market for Comprehensive Immune Profiling
  • Growth in Point-of-Care Testing Drives Demand for Rapid Multiplex Diagnostic Assays
  • Increasing Focus on Reducing Healthcare Costs and Improving Diagnostic Efficiency Expands Market for Multiplex Assays
  • Technological Advancements in Microfluidics and Lab-on-a-Chip Platforms Propel Growth in Multiplex Assay Development
  • Rising Adoption of Multiplex Assays in Vaccine Development Strengthens Business Case for High-Throughput Screening
  • Growth in Demand for Multiplex Assays in Infectious Disease Testing Expands Market for Pandemic Preparedness
  • Increasing Use of Multiplex Assays in Clinical Trials Drives Growth in Pharmaceutical and Biotechnology Applications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Protein Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 6: World 15-Year Perspective for Nucleic Acid Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 9: World 15-Year Perspective for Cell-based Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 12: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 15: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 18: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 21: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 24: World 15-Year Perspective for Hospitals & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 27: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 31: World Multiplex Assays Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
• FRANCE
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
• AUSTRALIA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION